Azizzadeh M, et al. - In patients treated for facial seborrheic dermatitis (FSD), a quicker response and fewer side effects were observed in those treated with pimecrolimus vs those who received sertaconazole.

• A total of 60 patients with FSD were asked to topically apply either pimecrolimus 1% cream (30 patients) or sertaconazole 2% cream (30 patients) twice daily for 4-weeks, in this double-blinded, and randomized trial.

• Both groups showed reduction in disease severity post-treatment, but a significant improvement was conferred by pimecrolimus vs sertaconazole on day 14 and day 28.

• The pimecrolimus group exhibited significantly lower rate of relapse than the sertaconazole after 28 days of treatment termination.

• Pimecrolimus was associated with the highest level of satisfaction (46.7%) on day 28.

• Both topical treatments showed acceptable safety, but more safety of pimecrolimus 1% cream than of sertaconazole 2% cream was evident in terms of irritation.